Candida parapsilopsis fungemias in bone marrow transplant recipients: implications for azole prophylactic therapy.
López-Jiménez
J
J
Duarte-Palomino
R
R
Cabezudo
E
E
Velasco-Martínez
J J
JJ
Sousa
A
A
Odriozola
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D015725:Fluconazole / Q000494:pharmacology / Q000627:therapeutic use*; D016469:Fungemia / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D017964:Itraconazole / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011183:Postoperative Complications
D000935:Antifungal Agents; D017964:Itraconazole; D015725:Fluconazole